Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441194 | 0.82 | FKBP1A (0.60) | ALDH1A1SMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL7452551 | 0.82 | FKBP1A (0.60) | ALDH1A1SMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL13995378 | 0.82 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL8544795 | 0.81 | FKBP1A (0.59) | ALDH1A1SMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL7276662 | 0.81 | ELANE (0.47) | ALDH1A1SMN1; SMN2CYP3A4FKBP1AKMT2A | |
| SCHEMBL24820758 | 0.81 | CYP3A4 (0.64) | ALDH1A1SMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL10144672 | 0.81 | CYP3A4 (0.64) | ALDH1A1SMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL7302729 | 0.81 | CYP3A4 (0.64) | ALDH1A1SMN1; SMN2CYP3A4CYP2C9PKM | |
| SCHEMBL8272580 | 0.80 | DPP4 (0.62) | ALDH1A1SMN1; SMN2PTGER4F2 | |
| SCHEMBL8545031 | 0.80 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CYP3A4CYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | ALDH1A1 3443/4885SMN1; SMN2 4398/4885CYP3A4 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.